A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis

Journal of Immunology

Volumn 193, Issue 5, 2014, Pages 2306-2316

  Beverley, Peter C L ^a   Ruzsics, Zsolt ^b   Hey, Ariann ^a   Hutchings, Claire ^a   Boos, Simone ^b   Bolinger, Beatrice ^a   Marchi, Emanuele ^a   O'Hara, Geraldine ^a   Klenerman, Paul ^a   Koszinowski, Ulrich H ^b   Tchilian, Elma Z ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

85A ANTIGEN; ADENOVIRUS VECTOR; ANTIBODY; ANTIGEN; ASIALO GANGLIO N TETRAOSYLCERAMIDE ANTIBODY; BCG VACCINE; CYTOMEGALOVIRUS VACCINE; INTERLEUKIN 21; M18 ANTIGEN; MURINE CYTOMEGALOVIRUS VACCINE; PP89 ANTIGEN; UNCLASSIFIED DRUG; EPITOPE; H2D ANTIGEN; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GROWTH INHIBITION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LUNG TUBERCULOSIS; MEMORY CELL; MICROARRAY ANALYSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; GENE VECTOR; GENETICS; IMMUNOLOGY; MUROMEGALOVIRUS; PATHOLOGY; TUBERCULOSIS, PULMONARY;

ANIMALS; EPITOPES; FEMALE; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGEN H-2D; INTERLEUKINS; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MUROMEGALOVIRUS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84907031435     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302523     Document Type: Article

References (61)

1. Comas, I., M. Coscolla, T. Luo, S. Borrell, K. E. Holt, M. Kato-Maeda, J. Parkhill, B. Malla, S. Berg, G. Thwaites, et al. 2013. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 45: 1176-1182.
2. Tameris, M. D., M. Hatherill, B. S. Landry, T. J. Scriba, M. A. Snowden, S. Lockhart, J. E. Shea, J. B. McClain, G. D. Hussey, W. A. Hanekom, et al.; MVA85A 020 Trial Study Team. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028.
3. Lalvani, A., S. Sridhar, and C. F. von Reyn. 2013. Tuberculosis vaccines: time to reset the paradigm? Thorax 68: 1092-1094.
4. Beverley, P. C. L., S. Sridhar, A. Lalvani, and E. Z. Tchilian. 2014. Harnessing local and systemic immunity for vaccines against tuberculosis. Mucosal Immunol. 7: 20-26.
5. Fine, P. E. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
6. Trunz, B. B., P. Fine, and C. Dye. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173-1180.
7. Velema, J. P., E. M. Alihonou, T. Gandaho, and F. H. Hounye. 1991. Childhood mortality among users and non-users of primary health care in a rural west African community. Int. J. Epidemiol. 20: 474-479.
8. Kleinnijenhuis, J., J. Quintin, F. Preijers, L. A. Joosten, D. C. Ifrim, S. Saeed, C. Jacobs, J. van Loenhout, D. de Jong, H. G. Stunnenberg, et al. 2012. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA 109: 17537-17542.
9. Jeyanathan, M., D. Damjanovic, C. R. Shaler, R. Lai, M. Wortzman, C. Yin, A. Zganiacz, B. D. Lichty, and Z. Xing. 2013. Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunol. 6: 612-625.
10. Plosa, E. J., J. C. Esbenshade, M. P. Fuller, and J. H. Weitkamp. 2012. Cytomegalovirus infection. Pediatr. Rev. 33: 156-163.
11. Boeckh, M. 2011. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology (Am. Soc. Hematol. Educ. Program) 2011: 305-309.
12. Masopust, D., and J. M. Schenkel. 2013. The integration of T cell migration, differentiation and function. Nat. Rev. Immunol. 13: 309-320.
13. Dekhtiarenko, I., M. A. Jarvis, Z. Ruzsics, and L. Čičin-Šain. 2013. The context of gene expression defines the immunodominance hierarchy of cytomegalovirus antigens. J. Immunol. 190: 3399-3409.
14. Tsuda, Y., P. Caposio, C. J. Parkins, S. Botto, I. Messaoudi, L. Cicin-Sain, H. Feldmann, and M. A. Jarvis. 2011. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl. Trop. Dis. 5: e1275.
15. Hansen, S. G., J. C. Ford, M. S. Lewis, A. B. Ventura, C. M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
16. Hansen, S. G., J. B. Sacha, C. M. Hughes, J. C. Ford, B. J. Burwitz, I. Scholz, R. M. Gilbride, M. S. Lewis, A. N. Gilliam, A. B. Ventura, et al. 2013. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340: 1237874.
17. Ziegler, H., W. Muranyi, H.-G. Burgert, E. Kremmer, and U. H. Koszinowski. 2000. The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. EMBO J. 19: 870-881.
18. Reusch, U., W. Muranyi, P. Lucin, H.-G. Burgert, H. Hengel, and U. H. Koszinowski. 1999. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J. 18: 1081-1091.
19. Kavanagh, D. G., M. C. Gold, M. Wagner, U. H. Koszinowski, and A. B. Hill. 2001. The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J. Exp. Med. 194: 967-978.
20. Kleijnen, M. F., J. B. Huppa, P. Lucin, S. Mukherjee, H. Farrell, A. E. Campbell, U. H. Koszinowski, A. B. Hill, and H. L. Ploegh. 1997. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 16: 685-694.
21. Forbes, E. K., C. Sander, E. O. Ronan, H. McShane, A. V. Hill, P. C. L. Beverley, and E. Z. Tchilian. 2008. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181: 4955-4964.
22. Xing, Z., C. T. McFarland, J. M. Sallenave, A. Izzo, J. Wang, and D. N. McMurray. 2009. Intranasal mucosal boosting with an adenovirusvectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE 4: e5856.
23. Dean, G., A. Whelan, D. Clifford, F. J. Salguero, Z. Xing, S. Gilbert, H. McShane, R. G. Hewinson, M. Vordermeier, and B. Villarreal-Ramos. 2014. Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine 32: 1304-1310.
24. Maninger, S., J. B. Bosse, F. Lemnitzer, M. Pogoda, C. A. Mohr, J. von Einem, P. Walther, U. H. Koszinowski, and Z. Ruzsics. 2011. M94 is essential for the secondary envelopment of murine cytomegalovirus. J. Virol. 85: 9254-9267.
25. Wagner, M., S. Jonjic, U. H. Koszinowski, and M. Messerle. 1999. Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J. Virol. 73: 7056-7060.
26. Jordan, S., J. Krause, A. Prager, M. Mitrovic, S. Jonjic, U. H. Koszinowski, and B. Adler. 2011. Virus progeny of murine cytomegalovirus bacterial artificial chromosome pSM3fr show reduced growth in salivary glands due to a fixed mutation of MCK-2. J. Virol. 85: 10346-10353.
27. Bosse, J. B., R. Bauerfeind, L. Popilka, L. Marcinowski, M. Taeglich, C. Jung, H. Striebinger, J. von Einem, U. Gaul, P. Walther, et al. 2012. A beta-herpesvirus with fluorescent capsids to study transport in living cells. PLoS ONE 7: e40585.
28. Bubeck, A., M. Wagner, Z. Ruzsics, M. Lötzerich, M. Iglesias, I. R. Singh, and U. H. Koszinowski. 2004. Comprehensive mutational analysis of a herpesvirus gene in the viral genome context reveals a region essential for virus replication. J. Virol. 78: 8026-8035.
29. Malin, A. S., K. Huygen, J. Content, M. Mackett, L. Brandt, P. Andersen, S. M. Smith, and H. M. Dockrell. 2000. Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. Microbes Infect. 2: 1677-1685.
30. Ronan, E. O., L. N. Lee, P. C. Beverley, and E. Z. Tchilian. 2009. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS ONE 4: e8235.
31. Battegay, M., S. Cooper, A. Althage, J. Bänziger, H. Hengartner, and R. M. Zinkernagel. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24-or 96-well plates. J. Virol. Methods 33: 191-198.
32. Kiessling, R., E. Klein, and H.Wigzell. 1975. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur. J. Immunol. 5: 112-117.
33. Holtappels, R., N. K. Grzimek, D. Thomas, and M. J. Reddehase. 2002. Early gene m18, a novel player in the immune response to murine cytomegalovirus. J. Gen. Virol. 83: 311-316.
34. D'Souza, S., V. Rosseels, M. Romano, A. Tanghe, O. Denis, F. Jurion, N. Castiglione, A. Vanonckelen, K. Palfliet, and K. Huygen. 2003. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71: 483-493.
35. Denis, O., A. Tanghe, K. Palfliet, F. Jurion, T. P. van den Berg, A. Vanonckelen, J. Ooms, E. Saman, J. B. Ulmer, J. Content, and K. Huygen. 1998. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect. Immun. 66: 1527-1533.
36. Pogoda, M., J. B. Bosse, F. M. Wagner, M. Schauflinger, P. Walther, U. H. Koszinowski, and Z. Ruzsics. 2012. Characterization of conserved region 2-deficient mutants of the cytomegalovirus egress protein pM53. J. Virol. 86: 12512-12524.
37. Osborn, J. E., and D. L. Walker. 1971. Virulence and attenuation of murine cytomegalovirus. Infect. Immun. 3: 228-236.
38. Reddehase, M. J. 2002. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2: 831-844.
39. Karrer, U., S. Sierro, M. Wagner, A. Oxenius, H. Hengel, U. H. Koszinowski, R. E. Phillips, and P. Klenerman. 2003. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J. Immunol. 170: 2022-2029.
40. Tchilian, E., D. Ahuja, A. Hey, S. Jiang, and P. Beverley. 2013. Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy. Vaccine 31: 4624-4631.
41. Sierro, S., R. Rothkopf, and P. Klenerman. 2005. Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. Eur. J. Immunol. 35: 1113-1123.
42. Snyder, C. M., K. S. Cho, E. L. Bonnett, S. van Dommelen, G. R. Shellam, and A. B. Hill. 2008. Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. Immunity 29: 650-659.
43. Kosaka, A., D. Wakita, N. Matsubara, Y. Togashi, S. Nishimura, H. Kitamura, and T. Nishimura. 2007. AsialoGM1+CD8+ central memory-type T cells in unimmunized mice as novel immunomodulator of IFN-γ-dependent type 1 immunity. Int. Immunol. 19: 249-256.
44. Nishikado, H., K. Mukai, Y. Kawano, Y. Minegishi, and H. Karasuyama. 2011. NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J. Immunol. 186: 5766-5771.
45. Herber, D., T. P. Brown, S. Liang, D. A. Young, M. Collins, and K. Dunussi-Joannopoulos. 2007. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J. Immunol. 178: 3822-3830.
46. Collins, M., M. J. Whitters, and D. A. Young. 2003. IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol. Res. 28: 131-140.
47. Kratholm, S. K., M. B. Iversen, L. Reinert, S. K. Jensen, M. Hokland, T. Andersen, A. Rankin, D. Young, S. Frische, S. R. Paludan, and C. K. Holm. 2013. Interleukin-21 receptor signalling is important for innate immune protection against HSV-2 infections. PLoS ONE 8: e81790.
48. Santosuosso, M., S. McCormick, X. Zhang, A. Zganiacz, and Z. Xing. 2006. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74: 4634-4643.
49. Mohr, C. A., L. Cîcîn-Saîn, M. Wagner, T. Sacher, M. Schnee, Z. Ruzsics, and U. H. Koszinowski. 2008. Engineering of cytomegalovirus genomes for recombinant live herpesvirus vaccines. Int. J. Med. Microbiol. 298: 115-125.
50. Cicin-Sain, L., I. Bubić, M. Schnee, Z. Ruzsics, C. Mohr, S. Jonjić, and U. H. Koszinowski. 2007. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J. Virol. 81: 13825-13834.
51. Trsan, T., A. Busche, M. Abram, F. M. Wensveen, N. A. Lemmermann, M. Arapovic, M. Babic, A. Tomic, M. Golemac, M. M. Brinkmann, et al. 2013. Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1g. Proc. Natl. Acad. Sci. USA 110: 16550-16555.
52. Barton, E. S., D. W. White, J. S. Cathelyn, K. A. Brett-McClellan, M. Engle, M. S. Diamond, V. L. Miller, and H. W. T. Virgin, IV. 2007. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447: 326-329.
53. Yager, E. J., F. M. Szaba, L. W. Kummer, K. G. Lanzer, C. E. Burkum, S. T. Smiley, and M. A. Blackman. 2009. g-Herpesvirus-induced protection against bacterial infection is transient. Viral Immunol. 22: 67-72.
54. Saederup, N., S. A. Aguirre, T. E. Sparer, D. M. Bouley, and E. S. Mocarski. 2001. Murine cytomegalovirus CC chemokine homolog MCK-2 (m131-129) is a determinant of dissemination that increases inflammation at initial sites of infection. J. Virol. 75: 9966-9976.
55. Mitrović, M., J. Arapović, L. Traven, A. Krmpotić, and S. Jonjić. 2012. Innate immunity regulates adaptive immune response: lessons learned from studying the interplay between NK and CD8+ T cells during MCMV infection. Med. Microbiol. Immunol. (Berl.) 201: 487-495.
56. Vidal, S. M., and L. L. Lanier. 2006. NK cell recognition of mouse cytomegalovirus-infected cells. Curr. Top. Microbiol. Immunol. 298: 183-206.
57. Toe, J. G., M. Pellegrini, and T. W. Mak. 2013. Promoting immunity during chronic infection: the therapeutic potential of common g-chain cytokines. Mol. Immunol. 56: 38-47.
58. Dou, J., Y. Wang, F. Yu, H. Yang, J. Wang, X. He, W. Xu, J. Chen, and K. Hu. 2012. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int. J. Immunogenet. 39: 183-190.
59. Aranday Cortes, E., D. Kaveh, J. Nunez-Garcia, P. J. Hogarth, and H. M. Vordermeier. 2010. Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice. PLoS ONE 5: e11319.
60. Cooper, A. M., K. D. Mayer-Barber, and A. Sher. 2011. Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 4: 252-260.
61. Portevin, D., and D. Young. 2013. Natural killer cell cytokine response to M. bovis BCG is associated with inhibited proliferation, increased apoptosis and ultimate depletion of NKp44+CD56bright cells. PLoS ONE 8: e68864.